Newron Pharmaceuticals - Dyskinesia deal delivered
Newron and Zambon will now progress the crucial Xadago Phase III study in Parkinson’s dyskinesia. This indication, if successful, should give an important boost to US sales. FY20 results showed Xadago royalties of €5.2m. Newron expects evenamide Phase II results in late March. This data on the novel schizophrenia drug could enable two Phase III studies to start from mid-2021. Newron hopes to partner evenamide for ‘inadequate response to current atypical antipsychotic agents’, a large indication. We estimate a deal might be signed from late Q321. Newron estimates it has about €61m available to fund development until late 2022. After an evenamide deal, it hopes to acquire further projects. Our current indicative value of CHF121m will be updated after evenamide Phase II data.Newron Pharmaceuticals is a clinical stage biopharmaceutical company. Co. is focused on the development of drugs for the treatment of central nervous system disorders and pain. Co.'s pipeline include, Xadago® (safinamide), for the treatment of Parkinson's disease (PD) and PD Levodopa-induced dyskinesia; Sarizotan, for the treatment of Rett syndrome (Orphan drug status); Evenamide (NW-3509), for the treatment of Schizophrenia and Clozapine-treatment-resistant schizophrenia; and Ralfinamide for patients with specific rare pain indications (neuropathic pain).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.